Skip to main content

Table 1 Baseline characteristics of cases, controls and the remainder of the RABBIT cohort

From: Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis

 

Cases

n = 112

Controls

n = 112

Remainder of the cohorta

n = 11,059

Matching criteria

   

Sex, male

48 (42.9)

48 (42.9)

2536 (22.9)

Age, years, mean (SD)

63.7 (9.1)

63.7 (9.1)

55.9 (12.5)

Hypertension

67 (60.4)

68 (60.7)

4102 (37.1)

Coronary heart disease

28 (25.2)

26 (23.2)

622 (5.6)

Heart failure

7 (6.3)

7 (6.3)

242 (2.2)

Previous cerebrovascular event

0 (0)

2 (1.8)

146 (1.3)

Hyperlipoproteinemia

19 (17.1)

18 (16.1)

869 (7.9)

Time to MI/index date, month, mean (SD)

31.0 (24.9)

29.5 (23.9)

NA

Unmatched criteria

   

Observation time, months, mean (SD)

52.6 (28.6)

60.2 (28.0)

44.4 (32.7)

Disease duration, years, mean (SD)

11.4 (10.6)

11.4 (9.4)

10.0 (9.1)

Rheumatoid factor positive

83 (74.1)

85 (75.9)

7942 (72.1)

CRP, mg/L, mean (SD)

23.5 (27.0)

16.5 (22.1)

18.4 (26.6)

ESR, mm/h, mean (SD)

39.2 (28.9)

30.7 (20.6)

31.3 (23.0)

DAS28, mean (SD)

5.6 (1.3)

5.5 (1.3)

5.2 (1.3)

FFbH, mean (SD)

53.1 (24.8)

58.4 (23.3)

63.0 (23.3)

Smoking, current

25 (22.3)

19 (17.0)

2355 (21.3)

Smoking, former

35 (31.3)

24 (21.4)

2589 (23.4)

Smoking, never

35 (31.3)

61 (54.5)

4698 (42.5)

Smoking, unknown

17 (15.2)

8 (7.1)

1417 (12.8)

BMI, mean (SD)

28.1 (5.6)

26.7 (4.0)

26.6 (5.3)

BMI ≥30 kg/m2

34 (30.4)

19 (17.0)

2514 (22.7)

Diabetes mellitus

26 (23.4)

14 (12.5)

1075 (9.7)

Chronic renal disease

11 (9.9)

8 (7.1)

397 (3.6)

COPD

12 (10.8)

13 (11.6)

495 (4.5)

No. of previous csDMARDs, mean (SD)

2.6 (1.4)

2.8 (1.5)

2.4 (1.3)

No. of previous bDMARDs, mean (SD)

0.5 (1.0)

0.4 (0.9)

0.3 (0.7)

Oral glucocorticoids

103 (93.6)

87 (77.7)

8788 (79.6)

Glucocorticoids, <5 mg/day

12 (10.9)

29 (25.9)

2981 (27.0)

Glucocorticoids, 5–10 mg/day

64 (58.2)

46 (41.1)

4997 (45.3)

Glucocorticoids, ≥10 mg/day

34 (30.9)

37 (33.0)

3048 (27.6)

Non-selective NSAIDs

47 (42.0)

39 (34.8)

4260 (38.5)

COX-2 inhibitors

17 (15.2)

23 (20.5)

1699 (15.4)

Any NSAIDs

62 (55.4)

62 (55.4)

5895 (53.3)

No CV treatmentb

27/75 (36.0)

13/75 (17.3)

967/4584 (21.1)

  1. Values are numbers of patients (%) unless otherwise specified. aPatients without myocardial infarction (MI) at follow-up and patients who were not matched controls. bNo cardiovascular (CV) treatment: one or more of the reported cardiovascular disease (CVD) at baseline (hypertension, coronary heart disease, heart failure or hyperlipoproteinaemia) is not reported as being treated
  2. BMI body mass index, SD standard deviation, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on 28 joints, FFbH Hannover Functional Status Questionnaire, COPD chronic obstructive pulmonary disease, csDMARD conventional synthetic disease-modifying antirheumatic drug, bDMARD biologic DMARD, NSAID nonsteroidal anti-inflammatory drug, COX-2 cyclooxygenase-2, NA not applicable. †P < 0.05 for comparison with cases (paired t test or Mc Nemar´s test). ‡P < 0.05 for comparison with cases (unpaired t test or chi-squared test)